NCT02082210 2020-12-19A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced CancerEli Lilly and CompanyPhase 1/2 Completed97 enrolled 20 charts
NCT01874938 2015-01-16A Study of LY2875358 in Participants With MET Positive, Advanced Gastric CancerEli Lilly and CompanyPhase 2 Completed15 enrolled